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Abstract 
Insulin resistance is a common finding in
hypertensive humans and animal models. The
Dahl salt-sensitive (S) rat is an ideal model of
genetically predetermined insulin resistance
and  salt-sensitive  hypertension.  Along  the
insulin signaling pathway, the insulin receptor
substrates 1 and 2 (IRS-1 and -2) are impor-
tant  mediators  of  insulin  signaling.  IRS-1
and/or  IRS-2  genetic  variant(s)  and/or
enhanced  serine  phosphorylation  correlate
with insulin resistance. The present commen-
tary  was  designed  to  highlight  the  signifi-
cance of IRS-1 and/or -2 in the pathogenesis of
insulin resistance. An emphasis will be given
to the putative role of IRS-1 and/or -2 genetic
variant(s) and serine phosphorylation in pre-
cipitating insulin resistance.
Insulin resistance is at the crossroads of
the cardiometabolic syndrome
Insulin resistance is a disorder character-
ized by the improper utilization of glucose by
the cells. This is because of an existing and/or
acquired  impairment  of  the  cell’s  ability  to
respond to exogenous or endogenous insulin.
This, in turn, results in β-cell compensation
failure and excessive blood glucose levels in
the midst of hyperinsulinemia.
1 Insulin resist-
ant subjects are predisposed to a cluster of
risk factors that increase their risk of having
cardiovascular  diseases.  These  risk  factors
include  high  blood  pressure,  obesity,  type  2
diabetes, elevated triglycerides, and lowered
high density lipoprotein cholesterol (HDL-C).
1
Alarmingly, over one third of Canadian adults
have insulin resistance,
2and about half of salt-
sensitive subjects are insulin resistant.
3 These
elevated  numbers  of  insulin  resistant  cases
reflect  the  enormous  economic  burden  that
comes from the treatment modalities of sever-
al  comorbidities  per  patient.  The  molecular
mechanism of insulin resistance in hyperten-
sion,  particularly  in  salt-sensitive  hyperten-
sion, is not fully characterized. Insulin resist-
ance might lead to hypertension because of
diminished insulin-induced vasodilation and
the imbalance between its pressor and depres-
sor effects.
1,4,5 In hypertension, there is resist-
ance  to  the  actions  of  insulin  on  glucose
uptake,  but  no  resistance  to  the  renal  and
sympathetic  actions  of  insulin.
6-9 These  sec-
ondary actions of insulin form the basis of the
insulin  hypothesis  of  hypertension.  This
hypothesis  proposes  that  the  compensatory
hyperinsulinemia  that  occurs  with  insulin
resistance increases sodium reabsorption and
sympathetic activity, which combine to cause
an increased vascular resistance and an ele-
vated  arterial  pressure.
6,10 Owing  to  the  fact
that insulin resistance in Dahl salt-sensitive
(S) rats precedes salt-sensitive hypertension
in  this  model,  we  directed  our  attention  to
highlighting the putative role of insulin recep-
tor substrates 1 and 2 (IRS-1 and -2) genetic
variants in the pathogenesis of insulin resist-
ance in Dahl S rats.
Insulin resistance in Dahl S rats
Dahl  S  rats  represent  an  ideal  model  of
insulin  resistance  syndrome  because  of  its
genetically predetermined insulin resistance,
11,12
hypertriglyceridemia,  abdominal  obesity,  and
salt-sensitive hypertension.
11 Regarding insulin
concentrations, Dahl rats in general have high-
er values for insulin concentration than control
Sprague Dawley rats implying their increased
genetic  susceptibility  to  insulin  resistance.
11
Additionally,  Dahl  S  rats  have  an  increased
serum insulin response to an oral glucose load
independent of different salt intakes compared
to  Dahl  salt-resistant  (R)  rats.
13 Regarding
insulin sensitivity, Dahl S rats have decreased
sensitivity  to  insulin,
14 as  evidenced  by  a
decreased insulin-stimulated glucose uptake by
skeletal muscles obtained from Dahl S vs. Dahl
salt-resistant  (R)  rats.
14 Regarding  insulin
receptors  distribution,  number,  and  affinity,
they were all comparable in skeletal muscle and
kidney of Dahl S and -R rats,
15with no change in
binding parameters in either group on high or
low  salt  chow.
15 Hepatic,  muscular,  and  renal
insulin receptor mRNA levels were comparable
in Dahl S and -R rats fed either low or high salt
chow.
15 Regarding the impact of salt diet, Dahl S
vs. -R rats had significant insulin resistance on
high salt diet (8% NaCl) for four weeks vs. nor-
mal salt diet.
14 Dahl S rats insulin resistance on
a high salt diet was characterized by an activa-
tion of the early steps in insulin signaling.
14 On
the other hand, salt retention was significantly
greater at weeks 1 and 2 in insulin-infused vs.
saline-infused Dahl S rats receiving 0.3% NaCl
vs. Dahl R rats, where insulin did not influence
sodium  retention,  mean  arterial  pressure,  or
plasma  epinephrine.
16 In  conclusion,  genetic
background and excessive sodium intake are
key factors contributing to the development of
insulin resistance and salt sensitive hyperten-
sion in Dahl S rats. The decreased sensitivity to
insulin in this model may involve a post-recep-
tor defect possibly a genetic variant(s) in the
IRS-1 and/or IRS-2 that contribute to their sus-
ceptibility to insulin resistance.
12,17
Insulin receptor substrates -1 and -2
Variations  in  candidate  genes  encoding
IRS-1 and -2 proteins involved in the insulin
signaling  pathway  may  be  implicated  in
insulin resistance. Insulin actions in skeletal
muscles, liver, kidney, fat, and brain result in
increased renal sodium retention, modulation
of transmembrane cation transport, induction
of  growth  promoting  effects  of  vascular
smooth muscle cells, and vascular hyperreac-
tivity.
18 The insulin signal transduction path-
way is initiated when insulin binds to a high-
affinity heterotetrameric transmembrane pro-
tein receptor that is present in all mammalian
cells.
4,18 The  insulin-receptor  complex  then
triggers  tyrosine  phosphorylation  of  second
Correspondence:  Marlene  Shehata,  207-1140
Fisher Avenue, K1Z 8M5, Ottawa, ON, Canada.
E-mail: marlenefouad@yahoo.com
Key words: Dahl S rats, insulin resistance, salt-
sensitivity,  insulin  signaling  pathway,  genetic
contributors, molecular contributors.
Received for publication: 12 May 2009
Revision received: 4 September 2009.
Accepted for publication: 4 September 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright M.F. Shehata 2009
Licensee PAGEPress, Italy
Heart International 2009; 4:e6
doi:10.4081/hi.2009.e6
Role of the IRS-1 and/or -2 in the pathogenesis of insulin resistance in
Dahl salt-sensitive (S) rats
Marlene F. Shehata
Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa,
Ottawa, ON, Canada
[page 22] [Heart International 2009; 4:e6]Article
[Heart International 2009; 4:e6] [page 23]
messengers, also called docking proteins, such
as the insulin receptor substrates-1, -2, -3, and
4 (IRS-1, -2, -3, and -4).
19-22 This in turn acti-
vates  the  phosphoinositide  3  kinase  (PI3K)
enzyme, the activation of which stimulates the
serine phosphorylation of Akt (Protein kinase
B).
18 The latter enzyme (PKB) stimulates glu-
cose transport in muscle and adipose tissue
through the translocation of the glucose trans-
porter GLUT4 isoform from the cytoplasm to
the plasma membrane.
23,24 PKB also stimulates
glycogen synthesis in the liver and muscle, and
stimulates  lipogenesis  in  adipose  tissue.
23,24
While IRS-3 and -4 play a role in cell growth
and differentiation, IRS-1 and -2 play an impor-
tant role in glucose metabolism. Genes encod-
ing for IRS-1 and/or -2 therefore may represent
attractive candidate genes to study for insulin
resistance. 
Associations between insulin resistance and
common variants in IRS-1 and -2 have been
reported  in  several  human  populations,
19,25-33
including  obese  Caucasian  children  and
adults, Asian Indians, Mexicans, and African-
Americans. Mechanisms underlying the contri-
butions  of  IRS-1 and/or  IRS-2  variants  to
insulin resistance include
34: (i) altered expres-
sion and/or function of IRS-1 and/or -2; (ii)
diminished  IRS-1  and/or  -2  binding  to  the
insulin receptor; (iii) hindered binding of IRS-
1  and/or  -2  variant(s)  to  the  p85  regulatory
subunit of the PI3-kinase and a decreased PI3-
kinase  activity.  As  a  result,  a  decrease  in
GLUT4 translocation to the plasma membrane
and a reduced glucose transport and glycogen
synthesis will ensue. Additionally, an impair-
ment  in  the  ability  of  IRS-1  and/or  -2  to
decrease phosphorylation of glycogen synthase
kinase-3 (GSK-3), an enzyme that is important
in  glycogen  synthesis,  will  reduce  glycogen
synthesis;  and  (iv)  decreased  IRS-1  protein
levels that are not counterbalanced by a con-
comitant increase in the IRS-2 protein content.
This, in turn, causes a reduction in insulin-
stimulated  PI3-kinase  activity  and  a  signifi-
cant  decrease  in  Akt  phosphorylation  and
activity.  In  conclusion,  IRS-1  and/or  -2  vari-
ant(s)  appear  to  contribute  to  the  impaired
ability  of  insulin  to  activate  the  IRS/PI3-
kinase/Akt/GSK-3  signaling  pathway,  which
ultimately results in defects in glucose trans-
port and glycogen synthesis.
Is it the IRS-1 and/or -2 genetic variations,
or the enhanced IRS-1 and/or -2 serine
phosphorylation, or both that predispose
Dahl S rats to insulin resistance?
IRS-1 and -2 tyrosine phosphorylation acti-
vates IRS proteins to bind to signaling mole-
cules in the insulin signaling pathway (such
as PI3K).
20,21 On the other hand, serine phos-
phorylation of IRS proteins attenuates insulin
signaling and explains an additional mecha-
nism  of  insulin  resistance  in  rodents.
35 For
example, increased serine phosphorylation of
IRS-1  was  demonstrated  in  the  liver  of  an
insulin  resistant  rat  model,
35 supporting  the
role of serine phosphorylation in precipitating
insulin resistance in this model. Owing to the
fact that IRS proteins have three times more
serine residues than tyrosine residues,
3,1 the
significance  of  serine  phosphorylation  has
been markedly highlighted. Serine phosphory-
lation of IRS-1 and IRS-2 can suppress insulin
signaling
36-39 in the following ways: it can (i)
allow  dissociation  of  IRS  proteins  from  the
insulin receptor; (ii) diminish tyrosine phos-
phorylation on usual sites by covering up phos-
phorylation sites and enhancing the release of
IRS proteins from intracellular complexes that
maintain them in close proximity to the recep-
tor; (iii) enhance IRS proteolytic degradation;
or (iv) switch IRS proteins to inhibitors of the
insulin receptor.
It  is  worth  mentioning  at  this  point  that
Dahl S rats have chronic hyperinsulinemia,
11
which potentially might enhance serine phos-
phorylation  of  IRS-1  and/or  -2
39 and  possibly
explain  an  additional  mechanism  of  insulin
resistance in Dahl S rats.
Perspectives
Knowledge of which genetic variants along
the insulin signaling pathway are important in
the genesis of salt-dependent insulin resist-
ance (a disease that comprises a large sub-
group [over 30%] of Canadian adults) would
enhance the understanding of the basic patho-
physiology of the disease. In addition it may
create  one  or  more  specific  targets  for  the
development of a novel anti-insulin resistance
drug  or  gene  therapy.  Variations  in  genes
encoding the IRS-1 or -2 proteins might be at
the level of DNA (genetic variants) or at the
level  of  serine  phosphorylation  as  explained
above. 
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